Simulations Plus Spring School Draws Record Crowd, Signaling MIDD Adoption
Event summary
- Simulations Plus' 2026 Spring School concluded March 27, 2026, with over 1,400 participants from 65 countries.
- The program offered two tracks: GastroPlus® Spring School and MonolixSuite™ Spring School, focused on PBPK and pharmacometrics respectively.
- The Spring School builds on Simulations Plus' existing educational initiatives, including Summer and Autumn Schools, and the University+ program.
- Jonathan Chauvin, Co-Chief Product and Technology Officer, emphasized the importance of consistent model-informed approaches across teams.
The big picture
Simulations Plus' Spring School highlights the increasing importance of model-informed drug development (MIDD) as a standard practice within the biopharmaceutical industry. The program's scale—over 1,400 participants—underscores the growing demand for specialized training and expertise in this area, potentially reducing reliance on traditional, resource-intensive clinical trials. This trend positions Simulations Plus as a key enabler of a more efficient and data-driven drug development process.
What we're watching
- Adoption Rate
- The rapid growth in Spring School participation suggests accelerating adoption of MIDD, but the ability of biopharma companies to integrate these methods into core workflows remains to be seen.
- Competitive Landscape
- Simulations Plus' dominance in MIDD training could attract competitors, potentially leading to price pressure or a fragmentation of standards within the industry.
- Regulatory Impact
- Increased reliance on MIDD may influence regulatory review processes, and the extent to which agencies will accept model-driven data will shape the future of drug development.
Related topics